| |
|
The public company's lead drug candidate NV-387, a drug that treats RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and other respiratory viral infections as well as Monkey-pox, has successfully completed Phase 1 clinical trials.
A broad-spectrum antiviral drug such as this one would be a highly desirable drug globally because it would enable treatment of patients as soon as they present symptoms of a viral disease without waiting for a test to identify a specific type of viral infection. What else does this? Antibiotics.
The technology behind this could completely transform the way viruses and their variants are treated worldwide and there's a good chance this public company holds the golden ticket.
As biotech stages a big comeback, this is a company you'll want to have on your radar. Click here to learn more about the incredible investment opportunity this organization may provide.
|
